A 79-Year-Old Woman With Stage IIIB Lung Squamous Cell Carcinoma Presenting With Late-Onset Durvalumab‑Associated Myocarditis Requiring Differentiation From Pericardial Invasion

Key Result

Durvalumab therapy was associated with late-onset myocarditis requiring differentiation from pericardial invasion in a 79-year-old woman with stage IIIB lung squamous cell carcinoma.

Key Points

• To describe a case of late-onset myocarditis in a patient receiving durvalumab therapy for lung cancer.
• Case report of a 79-year-old woman with stage IIIB lung squamous cell carcinoma.
• Examined symptoms and imaging to differentiate myocarditis from pericardial invasion.
• Detailed clinical observations and treatment responses.
• The patient developed symptoms consistent with myocarditis after starting durvalumab treatment.
• Diagnostic imaging was crucial in distinguishing myocarditis from pericardial invasion.
• The case highlights potential complications of immunotherapy in older patients.